Please login to the form below
difficult-to-treat cancers
This page shows the latest difficult-to-treat cancers news and features for those working in and with pharma, biotech and healthcare.
Tavros Therapeutics and Vividion Therapeutics collaborate in oncology programmes
Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal. ... undruggable. “We’re thrilled to launch our work with Vividion and harness our combined expertise to reach patients with difficult-to-treat cancers by
Latest news
-
Genentech and ArsenalBio join to identify successful T-cell oncology therapies
While CAR-T therapy has shown promise in blood cancers, solid tumours present additional challenges. ... be crucial in providing important therapies for difficult to treat cancers.".
-
Regeneron set to acquire Checkmate for approximately $250m
a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers. ... We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.".
-
Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of Kite.
-
Cancer Research UK and Teon Therapeutics announce treatment of first patient in phase 1/2 trial for difficult-to-treat cancers
dosed adenosine receptor antagonist, TT-702, for the treatment of patients with a range of difficult-to-treat cancers. ... treat cancers, which is why we are so delighted that we have successfully advanced TT-702 into human trials with Teon, safely
-
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy. ... The phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck share in
More from news
Approximately 1 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Amgen Oncology, one of the leading developers of innovative therapies for novel targets in difficult-to-treat cancers, is working to bring new hope for transforming clinical outcomes for patients with ... Visit AmgenOncology.com to learn more about the
-
A snapshot of Crescendo Biologics
What is the central focus of Crescendo’s research? The company is focused on T-cell enhancement to develop new ways to treat difficult cancer types. ... success – or to make advances in those cancers that are still difficult to treat in this way.
-
Radiosurgery innovation
Radiosurgery has greatest application in patients with difficult-to-treat cancers such as brain tumours. ... This was a tough ask of Pegasus as our technology is highly complex and it can be difficult to get journalists to understand its potential, let
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Actinic keratosis – a common skin condition that can lead to skin cancer
- The paper trail
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
No results were found
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
